The path to a successful vaccine adjuvant - 'The long and winding road'

Drug Discovery Today

Volumn 14, Issue 11-12, 2009, Pages 541-551

  O'Hagan, Derek T ^a   De Gregorio, Ennio ^b  

^a Novartis Vaccines Cambridge   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; ALUMINUM POTASSIUM SULFATE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; FLAGELLIN; FREUND ADJUVANT; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INTERLEUKIN 1BETA; ISCOM; LECTIN RECEPTOR; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; PREPANDRIX; PROTEIN MD 2; QS 21; RNA VACCINE; SCAVENGER RECEPTOR; SORBITAN ESTER; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIROSOME; WART VIRUS VACCINE;

ABSCESS; ANTIBODY RESPONSE; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMULSION; GENITAL HERPES; HUMAN; IMMUNOGENICITY; INFLUENZA; INNATE IMMUNITY; NONHUMAN; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AUTOIMMUNE DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; VACCINES;

EID: 67349087922     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.02.009     Document Type: Review

References (105)

1. Ramon G. Procédés pour accroitre la production des antitoxines. Ann. Inst. Pasteur 40 (1926) 1-10
2. O'Hagan D.T., and Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discov. 2 (2003) 727-735
3. Seubert A., Monaci E., Pizza M., O'Hagan D.T., and Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J. Immunol. 180 8 (2008) 5402-5412
4. Mosca F., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 23 (2008) 23
5. Schijns V.E. Induction and direction of immune responses by vaccine adjuvants. Crit. Rev. Immunol. 21 (2001) 75-85
6. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5 (2007) 505-517
7. Glenny A.T., et al. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol. 29 (1926) 31-40
8. Clements C.J., and Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20 (2002) S24-33
9. Freund J., et al. Sensitization and antibody formation after injection of turbecle bacili and paraffin oil. Proc. Soc. Exp. Biol. Med. 37 (1937) 509-513
10. Herbert W.J. The mode of action of mineral-oil emulsion adjuvants on antibody production in mice. Immunology 14 (1968) 301-318
11. Kreuter J., et al. The use of new polymethylmethacrylate adjuvants for split influenza vaccines. Exp. Cell Biol. 44 (1976) 12-19
12. Allison A.G., and Gregoriadis G. Liposomes as immunological adjuvants. Nature 252 (1974) 252
13. Ellouz F., Adam A., Ciorbaru R., and Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59 4 (1974) 1317-1325
14. Siddiqui W.A., et al. Vaccination of experimental monkeys against Plasmodium falciparum: a possible safe adjuvant. Science 201 (1978) 1237-1239
15. Woodhour A.F., et al. Hyperpotentiation by synthetic double-stranded RNA of antibody responses to influenza virus vaccine in adjuvant 65. Proc. Soc. Exp. Biol. Med. 131 (1969) 809-817
16. Vogel F.R., and Powell M.F. A compendium of vaccine adjuvants and excipients. In: Powell M.F., and Newman M.J. (Eds). Vaccine Design: The Subunit and Adjuvant Approach (1995), Plenum Press pp. 141-228
17. O'Hagan D.T. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6 (2007) 699-710
18. Metcalfe I.C., and Gluck R. Virosomes for vaccine delivery. In: Schijns V., and O'Hagan D.T. (Eds). Immunopotentiators in Modern Vaccines (2006) 179-189 (Chapter 11)
19. de Bruijn I.A., et al. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 23 Suppl. 1 (2005) S39-49
20. Singh M., et al. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine 24 (2006) 1680-1686
21. Leroux-Roels I., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007) 580-589
22. Levie K., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198 (2008) 642-649
23. Harper D.M., et al. Sustained efficacy up to 4, 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
24. Boland G., et al. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 23 (2004) 316-320
25. Garcon N., et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6 (2007) 723-739
26. Vandepapeliere P., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26 (2008) 1375-1386 (Epub 2008 Jan 1314)
27. Stoute J.A., et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J. Infect. Dis. 178 (1998) 1139-1144
28. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat. Biotechnol. 25 (2007) 1361-1366
29. Stephenson I., et al. Development and evaluation of influenza pandemic vaccines. Lancet Infect. Dis. 6 (2006) 71-72
30. 4 on purified influenza virus hemagglutinins in man. J. Immunol. 100 (1968) 1139-1140
31. Salk J.E., et al. The use of adjuvants in studies on influenza immunization. II. Increased antibody formation in human subjects inoculated with influenza virus vaccine in a water in-oil emulsion. Am. J. Hyg. 55 (1952) 439-456
32. Davenport F.M. Seventeen years' experience with mineral oil adjuvant influenza virus vaccines. Ann. Allergy 26 (1968) 288-292
33. Beebe G.W., et al. Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953. Am. J. Epidemiol. 95 (1972) 337-346
34. Aucouturier J., et al. The use of oil adjuvants in therapeutic vaccines. Vaccine 24 Suppl. 2 (2006) S2-44-45
35. Schijns V.E., and Degen W.G. Vaccine immunopotentiators of the future. Clin. Pharmacol. Ther. 82 (2007) 750-755 (Epub 2007 October 2003)
36. Hilleman M.R., et al. Studies for safety of adjuvant 65. Ann. Allergy 30 (1972) 477-483
37. Murray R., et al. Mineral oil adjuvants: biological and chemical studies. Ann. Allergy 30 (1972) 146-151
38. Schiller J.T., et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 Suppl. 10 (2008) K53-61
39. Verstraeten T., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Impact of universal varicella vaccination on 1-year-olds in Uruguay: 1997-2005. Vaccine 7 (2008) 7
40. Ishizaka S.T., and Hawkins L.D. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev. Vaccines 6 (2007) 773-784
41. Schultze V., et al. Safety of MF59 adjuvant. Vaccine 26 (2008) 3209-3222 Epub 2008 Apr 3221
42. Keitel W., et al. Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant. Vaccine 11 (1993) 909-913
43. Keefer M.C., et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 12 (1996) 683-693
44. Ott G., et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 13 (1995) 1557-1562
45. Cataldo D.M., and Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15 (1997) 1710-1715
46. O'Hagan D.T., et al. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin. Pharmacol. Ther. 82 (2007) 740-744 (Epub 2007 October 2031)
47. Corey L., et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials Chiron HSV Vaccine Study Group [see comments]. JAMA 282 (1999) 331-340
48. Straus S.E., et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J. Infect. Dis. 176 (1997) 1129-1134
49. Langenberg A.G., et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected] [published erratum appears in Ann. Intern. Med. 1995 Sep 1;123(5):395]. Ann. Intern. Med. 122 (1995) 889-898
50. Mascola J.R. Herpes simplex virus vaccines - why don't antibodies protect?. JAMA 282 (1999) 379-380
51. Nitayaphan S., et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 18 (2000) 1448-1455
52. Heineman T.C., et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17 (1999) 2769-2778
53. Lindblad E.B. Aluminium adjuvants - in retrospect and prospect. Vaccine 22 (2004) 3658-3668
54. Morefield G.L., et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23 (2005) 1588-1595
55. Dupuis M., et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell. Immunol. 186 (1998) 18-27
56. Akira S., et al. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
57. Pulendran B., and Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006) 849-863
58. Kawai T., and Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17 (2005) 338-344
59. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5 (2004) 987-995
60. van Duin D., et al. Triggering TLR signaling in vaccination. Trends Immunol. 27 (2006) 49-55
61. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
62. Jin M.S., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130 (2007) 1071-1082
63. Kim H.M., et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130 (2007) 906-917
64. Liu L., et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320 (2008) 379-381
65. Gavin A.L., et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314 (2006) 1936-1938
66. Nemazee D., et al. Immunology: Toll-like receptors and antibody responses. Nature 441 (2006) (E4; discussion E4)
67. Takeuchi O., and Akira S. MDA5/RIG-I and virus recognition. Curr. Opin. Immunol. 20 (2008) 17-22
68. Shaw M.H., et al. NOD-like receptors (NLRs): bona fide intracellular microbial sensors. Curr. Opin. Immunol. 20 (2008) 377-382
69. Petrilli V., et al. The inflammasome: a danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19 (2007) 615-622
70. Martinon F., et al. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr. Biol. 14 (2004) 1929-1934
71. Eisenbarth S.C., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126
72. Franchi L., and Nunez G. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity. Eur. J. Immunol. 38 (2008) 2085-2089
73. Li H., et al. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J. Immunol. 181 (2008) 17-21
74. De Gregorio E., et al. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38 (2008) 2068-2071
75. Boscardin S.B., et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J. Exp. Med. 203 (2006) 599-606
76. Napolitani G., et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6 (2005) 769-776
77. Fritz J.H., et al. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Eur. J. Immunol. 35 (2005) 2459-2470
78. Rimaniol A.C., et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 22 (2004) 3127-3135
79. Ulanova M., et al. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect. Immun. 69 (2001) 1151-1159
80. Li H., et al. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J. Immunol. 178 (2007) 5271-5276
81. Kool M., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J. Exp. Med. 205 (2008) 869-882
82. Dupuis M., et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur. J. Immunol. 31 (2001) 2910-2918
83. Mosca F., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10501-10506
84. O'Hagan D.T., et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20 (2002) 3389-3398
85. Vajdy M., et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J. Gen. Virol. 87 Pt 8 (2006) 2253-2262
86. Wack A., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26 (2008) 552-561
87. Litwin S.D., and Singer J.M. The adjuvant action of latex particulate carriers. J. Immunol. 95 (1965) 1147-1152
88. Raychaudhuri S., and Rock K.L. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 16 (1998) 1025-1031
89. Artursson P., et al. Biodegradable microspheres. III: some immunological properties of polyacryl starch microparticles. J. Pharm. Sci. 75 (1986) 697-701
90. O'Hagan D.T., et al. Microparticles as potentially orally active immunological adjuvants. Vaccine 7 (1989) 421-424
91. O'Hagan D.T., et al. Biodegradable microparticles as controlled release antigen delivery systems. Immunology 73 (1991) 239-242
92. Gupta R.K., et al. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. Adv. Drug Deliv. Rev. 32 (1998) 225-246
93. Singh M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J. Pharm. Sci. 93 (2004) 273-282
94. Kazzaz J., et al. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release 67 (2000) 347-356
95. Singh M., et al. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res. 18 (2001) 1476-1479
96. Kazzaz J., et al. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release 110 (2006) 566-573
97. Singh M., et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 65 (1997) 1716-1721
98. Wendorf J., et al. A practical approach to the use of nanoparticles for vaccine delivery. J. Pharm. Sci. 95 (2006) 2738-2750
99. Wendorf J., et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum. Vaccin. 4 (2008) 44-49 (Epub 2007 August 2015)
100. Sharp F.A., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 870-875 (Epub 2009 January 2012)
101. Wille-Reece U., et al. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 174 (2005) 7676-7683
102. Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2 (1980) 370-383
103. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6 (2006) 823-835
104. Wraith D.C., et al. Vaccination and autoimmune disease: what is the evidence?. Lancet 362 (2003) 1659-1666
105. Eickhoff T.C., and Myers M. Workshop summary. Aluminum in vaccines. Vaccine 20 Suppl. 3 (2002) S1-4